Clinical Trials
107 trialsNCT02364557 2026-05-19
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
NRG Oncology
Phase 2/3 Completed
NCT02635009 2026-05-19
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer
NRG Oncology
Phase 2/3 Completed
NCT02438722 2026-05-18
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2/3 Completed
NCT01744249 2026-04-28
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
Phase 2/3 Completed
NCT04396860 2026-04-22
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
NCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT02101788 2025-11-13
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT04838626 2025-10-07
GuideView
Novartis
Phase 2/3 Completed
NCT04862585 2025-08-20
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
Phase 2/3 Completed
NCT02763319 2025-07-17
B-MIND
Incyte Corporation
Phase 2/3 Completed
NCT04082364 2025-06-08
MAHOGANY
MacroGenics
Phase 2/3 Completed
NCT00922974 2025-04-29
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Radiation Therapy Oncology Group
Phase 2/3 Completed
NCT03822845 2025-04-17
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03357952 2025-02-04
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 2/3 Completed
NCT04499924 2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3 Completed
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT02784171 2024-12-10
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2/3 Completed
NCT01554397 2024-11-29
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
University of California, San Diego
Phase 2/3 Completed
NCT03389451 2024-07-12
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03579602 2024-06-27
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Blaze Bioscience Inc.
Phase 2/3 Completed
NCT02157974 2024-06-04
APPLE
University of Colorado, Denver
Phase 2/3 Completed
NCT04693637 2024-05-09
Prevent
AlloVir
Phase 2/3 Completed
NCT00837265 2024-04-03
NEUGR-002
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2/3 Completed
NCT01236560 2024-02-20
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03388346 2024-02-15
68Ga PSMA in Preprostatectomy Patients
University of Iowa
Phase 2/3 Completed
NCT03414983 2023-11-18
CheckMate 9X8
Bristol-Myers Squibb
Phase 2/3 Completed
NCT04145531 2023-11-18
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Jazz Pharmaceuticals
Phase 2/3 Completed
NCT03040726 2023-10-17
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT02068092 2023-10-10
Olive Oil for High Risk Breast Cancer Prevention in Women
The Methodist Hospital Research Institute
Phase 2/3 Completed
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT01428635 2023-09-26
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT03826628 2023-09-08
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Dermatology Specialties Limited Partnership
Phase 2/3 Completed
NCT01666808 2023-08-02
FACBC Outcomes for Post Prostatectomy
Emory University
Phase 2/3 Completed
NCT00424099 2023-06-01
Methylphenidate and a Nursing Telephone Intervention for Fatigue
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT02766335 2023-05-25
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network
Phase 2/3 Completed
NCT02624518 2023-04-10
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Stanford University
Phase 2/3 Completed
NCT02231879 2023-04-07
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
National Institutes of Health Clinical Center (CC)
Phase 2/3 Completed
NCT03103152 2023-03-29
PROVENT
Queen Mary University of London
Phase 2/3 Completed
NCT01818492 2023-02-21
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
Swedish Orphan Biovitrum
Phase 2/3 Completed
NCT02606461 2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3 Completed
NCT02910726 2022-10-05
A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
Memorial Sloan Kettering Cancer Center
Phase 2/3 Completed
NCT03410693 2022-09-28
FORT-1
Bayer
Phase 2/3 Completed
NCT02881957 2022-06-15
Hypovitaminosis D in Neurocritical Patients
University of Utah
Phase 2/3 Completed
NCT01164202 2022-03-18
SATURNE
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT02678351 2022-03-04
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Stanford University
Phase 2/3 Completed
NCT01518517 2022-02-02
GRASPIVOTALL
ERYtech Pharma
Phase 2/3 Completed
NCT02673151 2022-01-13
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Stanford University
Phase 2/3 Completed
NCT00177047 2021-11-09
Autologous Transplant for Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Phase 2/3 Completed